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Reactive oxygen species are involved in the activation of cellular 
phospholipase A2 
Rccrivcd 20 July 1992 
Vrntldatc (V) porcnliukd (4. lo IO-fold) tlrc ;trtir.;ltion of ccllr~lur phorphalipwz A: (PLA:) induscd by tl202 (H). ZI pharbol crkr (T), u 
Cur’4onaphorc (A) and oplrank~d xynwsw in macruphtiycr. V+H induced in inkul eelIs the uclivution and wztnrlacurian of PLA~~trntl pratcin 
kinrlc C (PKC) to the plnrmn nwmbnnc. V+tI ;ind V+T+A induced slrony chcmilumincrrcnrc (CL) which WIIL ubrogied by II ~rpccGc NADPH 
oxid;lr inhibitor diphcnylcnr iudonium (DPI). DPI mrwkcdly riuppmscd lhc sinrulalion of PLA: by V+T+A ;rnd V42. The results xuggcr~ Ihilt 
lhc formation of cndogcnour rrwivc oxygen *p&r (ROS) ir imptarlnnt fcrr %A, nctivution. 
Phospholipw A:: NADPH axidw: RcarGvc osggcn species: Diphcnglcnr iadoniunr: Vlmndak: Tyrosinc pralrin phosphu~nrc 
1, INTRODUCTION 
Phospholipasc AZ (PLA:) which rclcuscv ;lrtrchidonic 
ucid (AA) from phospholipids is u key cnzyrnc of the 
host-deface system. Ccllulrrr PLA: is uctivatcd by ng- 
onists such LLS antigen [I]. opsonizcd-zymoson (OZ) [2]. 
ll-O=tctrndectlnoyl phorbol 13.ticctiltC [T) [l-3], Ca” 
ionophorc A23187 (A) [l-3]. Since protein kinasc C 
(PKC) nnd tyrosine protein kinase (TDK) [\-4J take 
part in ugoniat uctivtrtion of PLA:, protein phosphoryl- 
ation on both tyrosinc und scrinc residues is essential to 
PLA: activation. 
Vanudutc (V) trod H20z (HI both enhance tyrosinc 
protein phosphorylation. und together they arc syncr- 
&tic (5-71. Their effect is mainly due to inhibition of 
tyrosinc protein phosphatascs (TPPrlsc) [6.7], V induced 
supcroxidc forrnution [S] and tyrosinc phosphoryhltion 
were prevented by diphcnylcnc iodonium (DPI) a spc- 
cific inhibitor of NADPH oxidilsc [S.S]. This suggests 
that cndogcnous reactive oxygen species (ROS), the 
products of NADPH oxidnsc, may bc csscntial for sup- 
pression of TPPasc activity [S], 
The objcctivcs of the present study were to dctcrminc: 
(a) whcthcr V potentiatcs the stimulntory activity of 
Cimmporrcfcrrrr rrrtctrcw: R. Goldman. Dcptirtmcni of Mcmbnnc Rc- 
search and Lliophysics, The Wcirmunn fnrtitutc of Scicncc. Rchovot 
76100, Isrucl. fix: (972) (8) 344112. 
Abbrcrtcrriuru: Y, vunudkuc; H. H,O,: DKC. protein hintisc C: PLA.. 
phospholipasc A,; TPPusc, tyrosinc prokin phorphuwsc; CL, chcmi- 
lumincsscncc; DPI, diphcnylcnc iodoniom; ROS, rcuclivc oxygn rpc- 
rif% A. c@’ ~nq3hore A23187: .AA. ztik!!k +d; T. f2*C). 
wndrcnnoyl phorbol 1%:w%lc: OZ. opvonircd xymorun: SI., YIUU. 
roaporine; Herb, A, hcrbimycin A; BMDM. bone murrow dcrivcd 
macrophugcs; Tg-Mo, thio~lycollutc-cliritcd pcritonwl mi\crophtigcs. 
T.A. 02 and H on PLAl activity. und (b) the possible 
role of cndogcnous ROS in tlrt regulation of ceitulsr 
PL& irctivity in n~slcrophirgc% 
2. EXPERIMENTAL 
2. I I hfrtrroplrcr#cx 
Thiaglycollak-elicitcd mouse (fcmk CDI) pcriloneul macro- 
pl~gcs (Tg-Ma) wcrc hnrvutcci and cultivtilcd for 96 h in 14~well 
Costnr plutcr (0.8~10’ Tg.Molwcll) iis described [9]. l3onc mxrw 
dcrivcd mncruph;~ycr (BMDM) wcrc cuhurcd in xurpcnrion ;IS Jc- 
wibcd [IO). 
Fcr dclcrminiltion of ccllulur PLA? acliviry. Tg-Mo wcrc prclahlcd 
for 16 h. with [‘Hk;lrachidanic ucid [‘HJAA; Amcrrhum) (0.1 ~Cikll) 
PL described previously [I 1. In brief. the cells were w~hed three times 
with H:mk’s b;k~nccd rnh solution (MWS). The amount of (‘C11AA 
mct~bolitcr clcwsd imo the medium (conluininy 0.58 rirtty ncid4r~ 
hovinc strum tdbumin (DSA)) BI il rcruh of the xpcikd trcutmcnki 
wuti dclcrnrincd ;md cxprcrrcd as % ofcell-incorporalcd [‘t&IA which 
WHY dctcrmincd on wlubilizcd cell monoluycrs. PL.42 and IIKC in 
mcmbrunc prcps~tions from DMDM wcm nrsuycd :is decribcd [iO]. 
Tg-Mo were gcmly scraped from cullurc dishes and ruspcndcd 
(3xlO~ccWml) in II luminol(O.2 mM)conlaininp MIX% supplcmcnlcd 
with 0.5% BSA and incubwzd ul 3O’C. V (0.5 mM), the rpecilicd 
nimul~ntr mid inhibitors wcrc rtddcd as intlicukd nnd CL was IIICPC 
urcd every ? nrin in 41 Lumun uppnrotus, model 2080 (Lumac fnstru- 
mcntr. 13i1rcl). 
3. RESULTS 
A combination of 0.S mM ortho-vnnadotc (Y) and 
0.2 mM H+& induced a 6 to lO.fold increase in the 
stimulation of_PLA? activity in Tg-MEI (Fig, la]. Addi- 
tion of V also murkcdly potcntiatcd the cffcct of OZ. T 
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Fig. I. Slimulelion of PLA, activity by vnnada:c (V) combined with 
t&O: 01) and various agonirrr. T&MU (a) und BMDM (b) HWC 
incuburcd with (blnckcncd bun) or without (cmpl:: bum) 0.5 mM V 
for 30 min at which point ~hc variousqonis~r wcrc rddcd und thcccllr 
wcrc furthor incubrtcd for M min. ‘The followingsganirtx were rrddcd: 
tl, 0.2 mM: opsonizcd xymosan (02). SCUI)rgM TPA (T). 100 nylml: 
CG ionaphorc A23117 (A). 2 PM: ;Ind T+A DI ubovc. C rrprcscnt% 
control cultures. The dirlu of (a) xc mczms of 4-6 cspsrimcnrr crch 
c;lrricd WI in rriplkxlc i S.E.M; (b) mmnr 01’6 cxpcrimcn;r curried 
OIII in triplitik The SD. did not cxccrd S-IO% 
v+Il VtT+A V&Z V*H V*T+A - 
Fip. 2. Effat of downq$ulelion of PKC Q) nnd inhibitors of PKC 
and TPK (b) on the octivrrtion of PLA, by various slimulnnta. To, 
rcprcscnrr an overnighl trculmcnt of TB_Mo wilh IOU ng/ml of the 
phorbal cer TPA. (10 T, trcnlcd nnd nonI:clllcd To.Mo wcrc incuD 
bstcd with V tend the rpccifisd addiGvcs IIL in Fig. IL (b) Tg-MO wcrc 
incub;rtcd for 30 min in buflcr with or without (C) rhc following 
inhibilors: L pM K25h, 0. I PM rt;rurorporine (SI.). I /rM GF 1082LUx 
or .IO~g/nrl hcrbimycin A (Herb. A). Y (0.5 mM) WIS lhcn added for 
30 min, und thon l’or uddhio~l60 min cilhcr0.2 mM H or IO0 ngfml 
T+*M A. Mc;lnr of rriplicllia f: SD. ofrr rcprcscnrirfivc spcrimcnl 
out of three. The bsul uctivhy (45%) was rublfuctd. 
and A on PLAl tlctivity (Fig. In). PLAl activity was 
directly mcusurcd in crude mcmbrtlnc prcpilrations iso- 
lated from BMDM treated with V+H. This trcacmcnt 
Icd to a susctlincd increase (2.5-fold) in membrane PLA, 
activity (Fig lb). 
WC next assessed the involvement of PKC and/or 
TPK in the activation of PLAI by V in combination 
with the vrrriour agonists. 
BMDM wcrc trctltcd with V (0.5 mM. 30 min) imd 
subscqucncly with or without H (0.2 mM. 60 min). V 01’ 
H alone did not uffcct PKC loc;lliz;ltion or activity in 
crude mcmbrancs isolutcd from the treated cells. but in 
V+H trciltcd cells the trctivicy of PKC in the mcmbruncs 
wus 1344 pmol/mg protcidmin as compared to I89 
pmoYmg protcin/min in cancrol cells. 
Down-regulation of PKC by overnight incubation of 
Tg-Mo with T completely abolished the concerted cffcct 
of V+OZ and V+T*A and supprcsscd by 50% the stim- 
ultltory effect of V+H on PLA? activity (Fig. 2~). Trcat- 
mcnt of Tg-Mo with PKC and TPK inhibitors; K252u. 
bisindolylmnlcimidc. GF 109203x (GF), rtaurasporinc 
and hcrbitnycin A Icd to a suppression (5664%) of 
PLA, activution by the combination of V+H, V+T+A 
(Fig. 2b) and V + OZ (not shown), 
DPI inhibited in it dose dependent manner the activa- 
tion of PLA: by the combination of Y+T+A, VtOZ 
and V+H (Fig. 33). The interaction of V+H with Tg-Me 
yicldcd a strong CL, indicating formation of ROS. This 
reaction was totally abolished by DPI (Fig. 3b). lncubu- 
tion of Tg-Me with V alone (0,s mM) or l-1 (0.2 mM) 
alone did not gcncrucc CL. Nor wcrc free radicals 
formed and CL gencratcd when Y +H wcrc combined in 
the absence of cells. The CL reaction induced by 
V+T+A and by V+H was suppressed by both PKC and 
TPK inhibitors (Fig. 3b and 3~). 
4. DlSCUSSION 
lndirccc observations suggest hat activation of PKC 
and TPK leads to activation of PLA2 [ 1,2,4]. PLAl acci- 
vation could not bc achieved in ii mutant devoid of TPK 
[4]. Purified PLA: was shown to undergo phosphoryla- 
tion by PKC. though the phosphorylation ulanc did not 
bring about enzyme xtivation II 11. Activators of PKC 
induce the trunslocntion of PLA2 to the plasma mcm- 
bronc [I, IO]. WC showed that treatment of BMDM with 
V+H cnhanccd PKC activity in ccl1 mcmbrtrncs and 
caused translocution of P&A2 to the membranes whtcv 
;:s zctivetion was sustained. MUrcovcr, inhibitors of 
DKC und TPK supprcsscd PLAJ activation by eny of 
the combinations tested (V+T+A. V+OZ and V+H). 
Activators of PKC including rhc combinutions of Y 
und the various agonists used, a5 well DS V nlonc (51. 
activacc NADPH oxidusc. WC and othsrs [12,13] have 
shown that inhibitors of PKC and TPK inhibit ROS 
formation. DPI, inhibits NADPH oxidnsc dircccly, by 
binding covnlcntly to its fhtvoprotein component IS]. 
The novel finding that the Y+H induced CL was also 
abolished by DPf, suggssts that ROS-radical formation 
cvcn with this combination is absolutely dcpcndcnt on 
an active NADPH oxidasc. VcNADPH have been 
shown to induss 0; formation in pcrmcnbilizcd HL-60 
cells [63. Vs’ + 0; product the highly rcaccivc V”-00 
(pcroxosanadatc) spccics [lrf]. Within the cells, Vs’ can 
be reduced to V’* by any one of scvcral reducing agents. 
but production of Y”-00 (probably) rsquircs cnzy- 
matically gencratcd 0: I A complex set of oxidation- 
reduction reactions involving 0:. H, V’*, V4*, NADPH 
and NADPH oxidusc lcnds to amplification of the oxi- 
dative potcntirrl within the ccl1 which results in inastiva- 
tion of about 60% of the acid phosphatase (tyrosinc 
protein phosphatitsc) activity in Tg-Ma (data not 
shown). It is likely chat the product of V and ROS is 
oxidizing an essential -SH group on the TPPasc molc- 
cult thereby causing the enzyme to lose its activity [151. 
W~siiggzsb ,,,YC .,.,..Y...“,. * ah..+ :ahAirinn &-!-!ZJpe gajyi[y & rqj~n. 
sible for suscoincd phosphorylation and activntion of 
PLA!. In various cell types TPPasc spccifis activity is IO 
to IOOO-fold higher than that of TPK 1161. 
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Fig. 3. The clTcct of DPI on PLAI aclivatlon (IL) and ROS formnlion 
(b,c) and the cffcct of PKC and TPK inhibitarr OI* r 9:: formution 
induced by Y+H (b) und Y+T+A (c). (3 TpMo wcrc incubntcd with 
the spccificd conscntmtions of DPI for 34 min and then lrcntcd with 
the stimulants OS in Fig. ?b; (band c) V (0.5 mM) with or without he 
specified mhibiton (ns in Fig. 2b) wcrc added (zero fimc) and chcmie 
lumincsccncc (CL) was mcasurcd cvcry 2 min in n Lumuc appnrutur. 
model 20110 (Lumac fnarumcnts. Rnssl). The stimulants H (0,2 mM) 
or T 100 ngIml+A (2pM) wcrc uddcd after IO min (arrow 1) nnd CL 
was measured for tin additional 20 min. DPl (4 )rM) WP~ added to 
control (Cont.: no inhibitor) cells at about 30 min (arrow 2) und CL 
wus further recorded. 
It yhoud bc borne in mind that V is used here as a 
transition metal inducing formation of potent ROS, 
Under physiological conditions, other transition metals 
such as Fe” or CU” may play this role [17,18]. 
WC conclude that optimal activation of PLAl cntnils 
at least two regulatory pathways actin in concert: (a) 
enzyme activation by PKC and TPK, and (b) attcnua- 
tion of the protein phosphatasc reaction that inactivates 
PLA,. Since activators of PLAI (02, T, A, and T+A) 
were potcntiatcd by V, and since their effects were 
markedly diminished by DPI, WC suggest hat PLAa 
activation was mainly via ROS formation and consc- 
qucntly TPPAsc inhibition. Stimulation of PLA, by 
V+H, a combination that could also inhibit TPPasc 
directly, was affected to a lesser dcgrec by inhibition of 
NADPH oxidasc. 
It is of interest hat ROS wsrc recently sugpcstcd to 
act as second messengers in platclcts aggregation in- 
duced by collagen 1193, in the metabolic effect induced 
by insulin in adipocytcs [?O] and in the activation of 
transcription factors [21,22]. 
In various pathologisal conditions, such ns inflammo- 
tion and allergy there is D locul elevation of ROS forma- 
tion which both induscs and exacerbates the manifesta= 
tion of chc pathology [17,181. DPI-like druSs which in- 
terfere with the formtltion of ROS could possibly be 
used to ollcvinte these conditions. 
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